Cognition Therapeutics to Showcase CT1812 Insights at CTAD 2024
Presenting prespecified analysis of cognitive impact on plasma p-Tau 217 subgroups in ‘SHINE'
In an exciting development for Alzheimer's disease research, Cognition Therapeutics, Inc., a leading clinical-stage company focusing on neurodegenerative disorders, has announced an oral presentation at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference. This conference is set to occur from October 29 to November 1, 2024.
Key Presentation Details
Dr. Michael Woodward, head of dementia research at Austin Health in Melbourne, Australia, will deliver insights from the Phase 2 ‘SHINE’ trial of CT1812. This study targets mild-to-moderate Alzheimer's disease, and Dr. Woodward's presentation promises to provide a comprehensive look at the positive outcomes observed in participants.
Positive Results from the SHINE Trial
According to Dr. Anthony O. Caggiano, Cognition's Chief Medical Officer, the trial's results indicate promising efficacy signals after six months of treatment with CT1812. Patients have demonstrated a favorable tolerability profile, substantiating the plans to further advance the drug's clinical development.
Important Findings from Related Research
In conjunction with the upcoming presentation, Cognition will also unveil the baseline characteristics from the 'SHIMMER' trial, revealing vital data about participants with dementia with Lewy bodies (DLB). This trial collects essential information regarding the severity of symptoms such as cognitive and movement impairments.
Presentation Scheduling
The conference will feature various presentations by Cognition Therapeutics, including:
- Oral Communication: Results from COG0201, a comprehensive analysis on CT1812 in the context of Alzheimer's disease.
- Poster Presentation: Baseline Data and early insights from the SHIMMER trial focusing on mild-to-moderate DLB.
Both presentations are designed to foster understanding of cognitive decline and treatment options in neurodegenerative conditions.
About CT1812
CT1812 is a groundbreaking small molecule designed to penetrate the blood-brain barrier and target the sigma-2 receptor complex. Preclinical and clinical data show that it effectively displaces harmful oligomers, which are implicated in neurodegenerative conditions such as Alzheimer's and DLB. This innovative approach aims to restore synaptic functions compromised by these disorders.
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is committed to developing therapeutic solutions for age-related degenerative disorders affecting the central nervous system. The company’s leading candidate, CT1812, is undergoing evaluation in multiple clinical settings, targeting diseases like Alzheimer's and DLB.
Clinical Development and Future Outlook
The advancements in CT1812 signify Hope for those affected by Alzheimer's disease, offering a distinct mechanism that differentiates it from other treatments currently available. The ongoing clinical trials aim to confirm the hypotheses surrounding CT1812's efficacy and pave the way for transformative treatment options.
Contact Information
If you wish to learn more about Cognition Therapeutics, please reach out to:
Cognition Therapeutics, Inc.
info@cogrx.com
For Media Inquiries:
Casey McDonald (media)
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
For Investor Relations:
Mike Moyer (investors)
LifeSci Advisors
mmoyer@lifesciadvisors.com
Frequently Asked Questions
What is CT1812?
CT1812 is an experimental drug developed by Cognition Therapeutics that targets the sigma-2 receptor complex to treat Alzheimer's disease.
Who will present at the CTAD conference?
Dr. Michael Woodward will present the findings from the Phase 2 'SHINE' trial on CT1812.
What are the results from the SHINE trial?
The trial showed positive efficacy signals and a favorable tolerability profile after six months of treatment.
What is the relevance of the SHIMMER trial?
The SHIMMER trial provides baseline characteristics of patients with dementia with Lewy bodies, offering insights into their symptoms.
How can I contact Cognition Therapeutics?
You can contact them via email at info@cogrx.com for general inquiries.
